المؤلفون: Jean Ferrieres, Eric Bruckert, Michel Farnier, Michel Krempf, Jean-Jacques Mourad, Baptiste Roux, Francois Schiele

المصدر: Journal of Comparative Effectiveness Research, Vol 12, Iss 4 (2023)

مصطلحات موضوعية: cardiologists, cardiovascular risk, case-vignette, ezetimibe, france, hypercholesterolemia, lipid-lowering, online interactive survey, statin, treatment, Public aspects of medicine, RA1-1270

الوصف: Aim: This online interactive survey investigated lipid-lowering approaches of French cardiologists in highand very high-cardiovascular risk patients with hypercholesterolemia. Materials & methods: Physicians assessed three hypothetical patients at three clinic visits, and selected the patients’ cardiovascular risk category, target low-density lipoprotein cholesterol (LDL-C) and treatment. Results: A total of 162 physicians completed 480 risk assessments; 58% of assessments correctly categorized the hypothetical patients. Most physicians chose the correct LDL-C target for one of the very high-risk patients, but higherthan- recommended targets were selected for the other very high-risk patient and the high-risk patient. Statins were the most commonly chosen treatment. Conclusion: French cardiologists often underestimate cardiovascular risk in patients with hypercholesterolemia, select a higher-than-recommended LDL-C target and prescribe less intensive treatment than that recommended by guidelines.

وصف الملف: electronic resource

Relation: https://doaj.org/toc/2042-6313

URL الوصول: https://doaj.org/article/1e8f7795c6074c6b9d7d1dc9fd397390

المؤلفون: Guillaume Besch, Sebastien Pili-Floury, Caroline Morel, Martine Gilard, Guillaume Flicoteaux, Lucie Salomon du Mont, Andrea Perrotti, Nicolas Meneveau, Sidney Chocron, Francois Schiele, Herve Le Breton, Emmanuel Samain, Romain Chopard

المصدر: Cardiovascular Diabetology, Vol 18, Iss 1, Pp 1-9 (2019)

مصطلحات موضوعية: Aortic disease, Transcatheter aortic valve implantation, Blood glucose, Glucose variability, Adverse events, Diseases of the circulatory (Cardiovascular) system, RC666-701

الوصف: Abstract Background Glycemic variability is associated with worse outcomes after cardiac surgery, but the prognosis value of early glycemic variability after transcatheter aortic valve implantation is not known. This study was therefore designed to analyze the prognosis significance of post-procedural glycemic variability within 30 days after transcatheter aortic valve implantation. Methods A post hoc analysis of patients from our center included in the FRANCE and FRANCE-2 registries was conducted. Post-procedural glycemic variability was assessed by calculating the mean daily δ blood glucose during the first 2 days after transcatheter aortic valve implantation. Major complications within 30 days were death, stroke, myocardial infarction, acute heart failure, and life-threatening cardiac arrhythmias. Results We analyzed 160 patients (age (median [interquartile] = 84 [80–88] years; diabetes mellitus (n) = 41 (26%) patients; logistic Euroscore = 20 [12–32]). The median value of mean daily δ blood glucose was 4.3 mmol l−1. The rate of major complications within 30 days after procedure among patients with the lowest quartile of glycemic variability was 12%, increasing from 12 to 26%, and 39% in the second, third, and fourth quartiles, respectively. In multivariate analysis, glycemic variability was independently associated with an increased risk of major complications within 30 days after the procedure (odds ratio [95% CI] = 1.83 [1.19–2.83]; p = 0.006). Conclusions This study showed that post-procedural glycemic variability was associated with an increased risk of major complications within 30 days after transcatheter aortic valve implantation. Trial registration Clinical trial registration number https://www.clinicaltrials.gov/; identifier: NCT02726958; date: April 4th, 2016

وصف الملف: electronic resource

Relation: http://link.springer.com/article/10.1186/s12933-019-0831-3; https://doaj.org/toc/1475-2840

URL الوصول: https://doaj.org/article/29c1b91b144e4c108355bd5261f3df53

المؤلفون: Johannes Grand, Francois Schiele, Christian Hassager, Jerry P Nolan, Abdo Khoury, Alessandro Sionis, Nikolaos Nikolaou, Katia Donadello, Wilhelm Behringer, Bernd W Böttiger, Alain Combes, Tom Quinn, Susanna Price, Pablo Jorge-Perez, Guido Tavazzi, Giuseppe Ristagno, Alain Cariou, Eric Bonnefoy Cudraz

المصدر: European Heart Journal. Acute Cardiovascular Care. 12:197-210

مصطلحات موضوعية: post-resuscitation care, acute cardiovascular care, resuscitation, Quality of care, cardiac arrest, quality indicators, General Medicine, Cardiology and Cardiovascular Medicine, Critical Care and Intensive Care Medicine, intensive care

الوصف: Aims Quality of care (QoC) is a fundamental tenet of modern healthcare and has become an important assessment tool for healthcare authorities, stakeholders and the public. However, QoC is difficult to measure and quantify because it is a multifactorial and multidimensional concept. Comparison of clinical institutions can be challenging when QoC is estimated solely based on clinical outcomes. Thus, measuring quality through quality indicators (QIs) can provide a foundation for quality assessment and has become widely used in this context. QIs for the evaluation of QoC in acute myocardial infarction are now well-established, but no such indicators exist for the process from resuscitation of cardiac arrest and post-resuscitation care in Europe. Methods and results The Association of Acute Cardiovascular Care of the European Society Cardiology, the European Resuscitation Council, European Society of Intensive Care Medicine and the European Society for Emergency Medicine, have reflected on the measurement of QoC in cardiac arrest. A set of QIs have been proposed, with the scope to unify and evolve QoC for the management of cardiac arrest across Europe. Conclusion We present here the list of QIs (6 primary QIs and 12 secondary Qis), with descriptions of the methodology used, scientific justification and motives for the choice for each measure with the aim that this set of QIs will enable assessment of the quality of postout-of-hospital cardiac arrest management across Europe.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bef7d272ee728e66465173e4e3ac77f7
https://doi.org/10.1093/ehjacc/zuad006

المؤلفون: Nadeem Qureshi, Sotiris Antoniou, Jan H. Cornel, Francois Schiele, Pasquale Perrone-Filardi, Johannes Brachmann, Eduard Sidelnikov, Guillermo Villa, Samara Ferguson, Christina Rowlands, José R. González-Juanatey

المساهمون: Qureshi, N., Antoniou, S., Cornel, J. H., Schiele, F., Perrone-Filardi, P., Brachmann, J., Sidelnikov, E., Villa, G., Ferguson, S., Rowlands, C., Gonzalez-Juanatey, J. R.

المصدر: Advances in Therapy, 40, 1, pp. 233-251
Advances in Therapy, 40, 233-251

مصطلحات موضوعية: All institutes and research themes of the Radboud University Medical Center, Dyslipidemia, Physician, Vascular damage Radboud Institute for Health Sciences [Radboudumc 16], Treatment pattern, Pharmacology (medical), General Medicine, Heart infarction, Guideline, Proprotein convertase 9

الوصف: Contains fulltext : 291332.pdf (Publisher’s version ) (Open Access) INTRODUCTION: The 2019 European Society of Cardiology and European Atherosclerosis Society (2019 ESC/EAS) guidelines stress the importance of managing low-density lipoprotein cholesterol (LDL-C) after myocardial infarction (MI) to reduce the risk of cardiovascular events. Information on guideline implementation is limited. The aim of this survey was to describe current clinical practice regarding LDL-C management in the first year post-MI across Europe, improving understanding of the role of ESC/EAS guidelines on clinical practice. METHODS: A qualitative web-based cross-sectional physician survey about the patient pathway and LDL-C management post-MI was conducted in 360 physicians from France, Italy, Germany, The Netherlands, Spain, and the UK (n = 60/country) between December 2019 and June 2020. Secondary and primary care physicians (SCPs/PCPs) described their experiences treating patients post-MI over the preceding 2 months. RESULTS: Physicians reported that on average 90.7% of patients not prescribed lipid-lowering therapy (LLT) before an MI initiated LLT as inpatients; for patients already taking LLT, treatment was intensified for 64.7% of inpatients post-MI. SCPs reported prescribing higher-intensity statins and/or ezetimibe for between 72.3% (Italy) and 88.6% (UK) of patients post-MI. More than 80.0% of SCPs and 51.2% of PCPs stated that they would initiate a change in LLT immediately if patients did not achieve their LDL-C treatment goal by 12 weeks post-MI; 82.0% of SCPs and 55.1% of PCPs reported referring to 2019 ESC/EAS guidelines for management of patients post-MI. Barriers to initiating PCSK9 inhibitors (PCSK9is) included prior prescription of a maximally tolerated dose of statin (49.4%) and/or ezetimibe (38.9%), requirement to reach threshold LDL-C levels (44.9%), and pre-authorization requirements (30.4%). CONCLUSION: Differences in clinical practice post-MI were reported across the countries surveyed, including divergence between 2019 ESC/EAS and local guidelines. Increased use of innovative medicines to achieve LDL-C goals should reduce risk of subsequent cardiovascular events in very high-risk patients post-MI. 01 januari 2023

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1cac31a996035c9f344231d48a909a61
https://hdl.handle.net/11588/917883

المؤلفون: Francois Schiele, Gregory Piazza, Gilles Capellier, Mathieu Besutti, Marc Badoz, Romain Chopard, Nicolas Meneveau, Nicolas Falvo, Fiona Ecarnot

المصدر: Chest. 160:1832-1843

مصطلحات موضوعية: Pulmonary and Respiratory Medicine, medicine.medical_specialty, Framingham Risk Score, Anemia, business.industry, Bleed, Critical Care and Intensive Care Medicine, medicine.disease, Logistic regression, Pulmonary embolism, Brier score, Internal medicine, medicine, Derivation, Cardiology and Cardiovascular Medicine, business, Major bleeding

الوصف: Background Improved prediction of the risk of early major bleeding in pulmonary embolism (PE) is needed to optimize acute management. Research Question Does a simple scoring system predict early major bleeding in acute PE patients, identifying patients with either high or low probability of early major bleeding? Study Design and Methods From a multicenter prospective registry including 2,754 patients, we performed post hoc multivariable logistic regression analysis to build a risk score to predict early (up to hospital discharge) major bleeding events. We validated the endpoint model internally, using bootstrapping in the derivation dataset by sampling with replacement for 500 iterations. Performances of this novel score were compared with that of the VTE-BLEED (Venous Thrombo-Embolism Bleed), RIETE (Registro informatizado de la enfermedad tromboembolica en Espana; Computerized Registry of Patients with Venous Thromboembolism), and BACS (Bleeding, Age, Cancer, and Syncope) models. Results Multivariable regression identified three predictors for the occurrence of 82 major bleeds (3.0%; 95% CI, 2.39%-3.72%): Syncope (+1.5); Anemia, defined as hemoglobin 2.5 points). Observed bleeding rates increased with increasing risk group, from 0.97% (95% CI, 0.53%-1.62%) in the low-risk to 8.93% (95% CI, 6.15%-12.44%) in the high-risk group. C-index was 0.74 (95% CI, 0.73-0.76) and Brier score 0.028 in the derivation cohort. Similar values were calculated from internal bootstrapping. Performance of the PE-SARD score was better than that observed with the VTE-BLEED, RIETE, and BACS scores, leading to a high proportion of bleeding-risk reclassification in patients who bled and those who did not. Interpretation The PE-SARD bleeding risk score is an original, user-friendly score to estimate risk of early major bleeding in patients with acute PE.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::38d0b4a8352c28ed5ccf34ffde9d2b79
https://doi.org/10.1016/j.chest.2021.06.048

المؤلفون: Charalambos Vlachopoulos, Marcello Arca, Francois Schiele, Leopoldo Pérez de Isla

المصدر: American Journal of Cardiovascular Drugs. 22:239-249

مصطلحات موضوعية: medicine.medical_specialty, Statin, medicine.drug_class, law.invention, Pharmacotherapy, Ezetimibe, Randomized controlled trial, law, Internal medicine, medicine, Humans, Pharmacology (medical), Adverse effect, Dyslipidemias, business.industry, Anticholesteremic Agents, PCSK9, Cholesterol, LDL, General Medicine, medicine.disease, Pill, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Proprotein Convertase 9, Cardiology and Cardiovascular Medicine, business, Dyslipidemia, medicine.drug

الوصف: Despite the availability of lipid-lowering therapies (LLTs) that are safe and effective, the overall rate of low-density lipoprotein cholesterol (LDL-C) control at a population level in real-life studies is low. Higher-intensity treatment, earlier intervention, and longer-term treatment have all been shown to improve outcomes. However, in clinical practice, actual exposure to LLT is a product of the duration and intensity of, and adherence to, the treatment. To increase exposure to LLTs, the European Society of Cardiology guidelines recommended a stepwise optimization of LLTs by increasing statin intensity to the maximally tolerated dose, with subsequent addition of ezetimibe and proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Evidence from randomized controlled trials performed in a range of patients suggested that adding ezetimibe to statins rather than doubling the statin dose resulted in significantly more patients at LDL-C goal and significantly fewer patients discontinuing treatment because of adverse events. In addition, data showed that combination treatments effectively increased exposure to LLT. Despite these data and recommendations, optimization of LLT is often limited to increasing statin dose. Therapeutic inertia and poor treatment adherence are significant and prevalent barriers to increasing treatment exposure. They are known to be influenced by pill burden and complexity of treatment. Single-pill combinations provide a strategic approach that supports the intensification of treatment without increasing pill burden or treatment complexity. Single-pill combinations, compared with free associations, have been shown to increase the adherence to LLT and the percentage of patients at LDL-C goal.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efe39f6dd1352c468a22e8416cc0660c
https://doi.org/10.1007/s40256-021-00498-2

المؤلفون: Etienne Puymirat, Gilles Lemesle, Clément Delmas, Vincent Bataille, Frédéric Bouisset, Jean Ferrières, Didier Blanchard, Fast-Mi investigators, Francois Schiele, Pierre Coste, Nadia Aissaoui, Pascal Motreff, Guillaume Cayla, Edouard Gerbaud, Nicolas Danchin, Tabassome Simon, Loic Belle

المصدر: Journal of the American College of Cardiology. 78:1291-1305

مصطلحات موضوعية: Male, medicine.medical_specialty, Acute coronary syndrome, Myocardial revascularization, Percutaneous, medicine.medical_treatment, Revascularization, Time-to-Treatment, Percutaneous Coronary Intervention, Internal medicine, Fibrinolysis, medicine, Humans, Registries, Myocardial infarction, Aged, business.industry, Mortality rate, Middle Aged, medicine.disease, Cardiology, ST Elevation Myocardial Infarction, Female, Observational study, France, Cardiology and Cardiovascular Medicine, business

الوصف: The optimal management of patients with ST-segment elevation myocardial infarction (STEMI) presenting late-12 hours following symptom onset-is still under debate.The purpose of this study was to describe characteristics, temporal trends, and impact of revascularization in a large population of latecomer STEMI patients.The authors analyzed the data of 3 nationwide observational studies from the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) program, conducted over a 1-month period in 2005, 2010, and 2015. Patients presenting between 12 and 48 hours after symptom onset were classified as latecomers.A total of 6,273 STEMI patients were included in the 3 cohorts, 1,169 (18.6%) of whom were latecomers. After exclusion of patients treated with fibrinolysis and patients deceased within 2 days after admission, 1,077 patients were analyzed, of whom 729 (67.7%) were revascularized within 48 hours after hospital admission. At 30-day follow-up, all-cause death rate was significantly lower among revascularized latecomers (2.1% vs 7.2%; P 0.001). After a median follow-up of 58 months, the rate of all-cause death was 30.4 (95% CI: 25.7-35.9) per 1,000 patient-years in the revascularized latecomers group vs 78.7 (95% CI: 67.2-92.3) per 1,000 patient-years in the nonrevascularized latecomers group (P 0.001). In multivariate analysis, revascularization of latecomer STEMI patients was independently associated with a significant reduction of mortality occurrence during follow-up (HR: 0.65 [95% CI: 0.50-0.84]; P = 0.001).Coronary revascularization of latecomer STEMI patients is associated with better short and long-term clinical outcomes.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e157104cab915fd6f2e130adbb33d22c
https://doi.org/10.1016/j.jacc.2021.07.039

المؤلفون: Nadia Quignot, D.A. Kahangire, G Gusto, L. Ricci, Francois Schiele, Jean-Vannak Chauny, Gaëlle Désaméricq, Artak Khachatryan, Guillermo Villa

المصدر: International Journal of Cardiology. 332:22-28

مصطلحات موضوعية: Male, medicine.medical_specialty, Statin, medicine.drug_class, Myocardial Infarction, 030204 cardiovascular system & hematology, Lower risk, 03 medical and health sciences, 0302 clinical medicine, Ezetimibe, Internal medicine, medicine, Humans, 030212 general & internal medicine, Myocardial infarction, Medical prescription, Aged, Proportional hazards model, business.industry, medicine.disease, Intensity (physics), Female, France, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiology and Cardiovascular Medicine, business, Mace, Follow-Up Studies, medicine.drug

الوصف: Background In patients at risk of cardiovascular (CV) events, the effectiveness of lipid-lowering therapies (LLT) is affected by both intensity and adherence. Our study evaluated the association between LLT intensity (statin and/or ezetimibe) and adherence, and CV events in patients with a history of myocardial infarction (MI) in France. Methods Using the French national healthcare database (SNDS), we included patients with a history of MI, an initial LLT prescription in 2011–2013, and a second prescription within one year. LLT intensity was defined using the expected percent reduction in low-density lipoprotein cholesterol; adherence was measured as the proportion of days covered. Cox proportional hazards models were used to assess associations between intensity and/or adherence, and the risk of major adverse CV event (MACE). Results 164,565 patients were included; mean (SD) age, 66·3 (13·8) years; 73·6% men. Following an MI, only half of patients were treated with high-intensity LLT and approximately 40% of those on LLT remained non-adherent during follow-up (mean (SD) follow-up, 2·6 (1·4) years). Each 10% increase in treatment intensity, adherence, or adherence-adjusted intensity was respectively associated with a 16% (HR 0.84, 95%CI 0.84–0.85), 7% (HR 0.93, 95%CI 0.93–0.94), and 15% (HR 0.85, 95%CI 0.84–0.86) decrease in the risk of MACE. Conclusions Among patients with a history of MI, prescriptions of high-intensity LLT were limited and adherence to LLT was low. Higher intensity and/or adherence to statins was associated with a significantly lower risk of MACE, highlighting the importance of compliance with clinical guidelines to improve patient outcomes.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f539beefc74b1489725bf68fb22abf2d
https://doi.org/10.1016/j.ijcard.2021.03.007

المؤلفون: Nicolas Danchin, Nicolas Meneveau, Chris P Gale, Héctor Bueno, Maddalena Lettino, Jean Ferrières, Francois Schiele, Keith A.A. Fox, Tabassome Simon, Etienne Puymirat, Marco Tubaro, Fiona Ecarnot

المصدر: European Heart Journal. Acute Cardiovascular Care. 10:207-215

مصطلحات موضوعية: medicine.medical_specialty, Multivariate analysis, business.industry, media_common.quotation_subject, Cardiology, Myocardial Infarction, General Medicine, Benchmarking, 030204 cardiovascular system & hematology, Critical Care and Intensive Care Medicine, medicine.disease, 03 medical and health sciences, 0302 clinical medicine, Emergency medicine, medicine, Humans, Quality (business), Registries, 030212 general & internal medicine, Myocardial infarction, Cardiology and Cardiovascular Medicine, business, Quality Indicators, Health Care, media_common

الوصف: Aims We estimated the 2020 European Society of Cardiology-Acute Cardio Vascular Care (ESC-ACVC) quality indicators (QI) for the management of acute myocardial infarction, from three existing registries to determine the feasibility of assessment, room for improvement, association with outcomes, and suitability for centre benchmarking. Methods and results Data were extracted from three French nationwide registries, namely FAST-MI 2005, 2010, and 2015. Feasibility of assessment and room for improvement were estimated by the denominator (patients in whom QI could be measured) and numerator (patients who satisfied the QI, among those eligible). Associations between composite QIs (CQIs) and mortality were assessed by multivariate analysis. Centre benchmarking was based on the centres mean CQI, vs. the national mean. The 2020 QIs were measured in 12 660/13 130 patients from FAST-MI. Measurement feasibility ranged from 15% to 100% with greater potential for implementation with the 2020 QI set. The mean (±SD) value of the opportunity-based CQI was 0.72 ± 0.01 and attainment of the all-or-none CQI 8.5%. Both CQIs were associated with adjusted 1-year mortality. Centre categorization into low, intermediate, and high quality was feasible, and distinguished centres with differing mortality. Conclusion Most of the 2020 QI can be measured from existing registries in all domains but not in the patient’s satisfaction domain. This assessment shows potential for implementation. Both CQIs were inversely associated with one-year mortality and centre benchmarking was feasible.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e11b4740041257d8658eb51eb6cd32da
https://doi.org/10.1093/ehjacc/zuab010

المؤلفون: Edouard Desjobert, Etienne Puymirat, Francois Schiele, Tabassome Simon, Fast-Mi investigators, Nicolas Danchin, Victoria Tea, Jean Ferrières

المصدر: Archives of Cardiovascular Diseases. 114:88-95

مصطلحات موضوعية: Male, medicine.medical_specialty, Time Factors, Statin, medicine.drug_class, medicine.medical_treatment, Population, 030204 cardiovascular system & hematology, Risk Assessment, 03 medical and health sciences, Percutaneous Coronary Intervention, 0302 clinical medicine, Recurrence, Risk Factors, Internal medicine, Secondary Prevention, medicine, Humans, Registries, 030212 general & internal medicine, Myocardial infarction, Practice Patterns, Physicians', Non-ST Elevated Myocardial Infarction, education, Stroke, Aged, Dyslipidemias, Aged, 80 and over, education.field_of_study, Framingham Risk Score, business.industry, Hazard ratio, General Medicine, Thrombolysis, Middle Aged, medicine.disease, Lipids, Drug Utilization, Patient Discharge, Confidence interval, Treatment Outcome, ST Elevation Myocardial Infarction, Female, France, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Cardiology and Cardiovascular Medicine, business, Biomarkers

الوصف: Summary Background Current guidelines strongly recommend high-intensity statin therapy after acute myocardial infarction. Aims To analyse the relationship between prescription of high-intensity statin therapy at discharge and long-term clinical outcomes according to risk level defined by the Thrombolysis In Myocardial Infarction Risk Score for Secondary Prevention (TRS-2P) after acute myocardial infarction. Methods We used data from the FAST-MI 2005 and 2010 registries — two nationwide French surveys including 7839 consecutive patients with acute myocardial infarction. Level of risk was stratified in three groups using the TRS-2P score: Group 1 (low risk; TRS-2P = 0–1); Group 2 (intermediate risk; TRS-2P = 2); and Group 3 (high risk; TRS-2P ≥ 3). Results Among the 7348 patients discharged alive with a TRS-2P available, high-intensity statin therapy was used in 41.3% in Group 1, 31.3% in Group 2 and 18.5% in Group 3. After multivariable adjustment, high-intensity statin therapy was associated with a non-significant decrease in major adverse cardiovascular events (death, stroke or recurrent myocardial infarction) at 5 years in the overall population compared with that in patients receiving intermediate- or low-intensity statins or without a statin prescription (14.3% vs 29.6%; hazard ratio 0.94, 95% confidence interval 0.81–1.09; P = 0.42). In absolute terms, the decrease in major adverse cardiovascular events was positively correlated with risk level (Group 1: 8.1% vs 10.7%; Group 2: 14.8% vs 21.6%; Group 3: 30.8% vs 51.6%). However, after adjustment, the benefits of high-intensity statin therapy were associated with lower mortality only in high-risk patients (hazard ratio 0.79, 95% confidence interval 0.64–0.97; P = 0.02). Conclusions High-intensity statin therapy at discharge after acute myocardial infarction was associated in absolute terms with fewer major adverse cardiovascular events at 5 years, regardless of atherothrombotic risk stratification, although the highest absolute reduction was found in the high-risk TRS-2P class.

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::df9c4d29f143ca93bd4538f0ae0898dc
https://doi.org/10.1016/j.acvd.2020.06.003